Neovasc Inc
TSX:NVCN
Intrinsic Value
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. [ Read More ]
The intrinsic value of one NVCN stock under the Base Case scenario is 7.37 CAD. Compared to the current market price of 40.15 CAD, Neovasc Inc is Overvalued by 82%.
Valuation Backtest
Neovasc Inc
Run backtest to discover the historical profit from buying and selling NVCN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Neovasc Inc
Current Assets | 29.8m |
Cash & Short-Term Investments | 25.8m |
Receivables | 2.5m |
Other Current Assets | 1.5m |
Non-Current Assets | 8.9m |
PP&E | 502.9k |
Other Non-Current Assets | 8.4m |
Current Liabilities | 10.1m |
Accounts Payable | 2.2m |
Accrued Liabilities | 2.6m |
Other Current Liabilities | 5.3m |
Non-Current Liabilities | 12.8m |
Long-Term Debt | 12.8m |
Other Non-Current Liabilities | 43.6k |
Earnings Waterfall
Neovasc Inc
Revenue
|
3.8m
USD
|
Cost of Revenue
|
-773.8k
USD
|
Gross Profit
|
3m
USD
|
Operating Expenses
|
-36.2m
USD
|
Operating Income
|
-33.2m
USD
|
Other Expenses
|
-8m
USD
|
Net Income
|
-41.2m
USD
|
Free Cash Flow Analysis
Neovasc Inc
NVCN Profitability Score
Profitability Due Diligence
Neovasc Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Neovasc Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
NVCN Solvency Score
Solvency Due Diligence
Neovasc Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Neovasc Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVCN Price Targets Summary
Neovasc Inc
Shareholder Return
NVCN Price
Neovasc Inc
Average Annual Return | -49.07% |
Standard Deviation of Annual Returns | 26.42% |
Max Drawdown | -97% |
Market Capitalization | 110.5m CAD |
Shares Outstanding | 2 759 220 |
Percentage of Shares Shorted | 0.05% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures and markets products for the cardiovascular marketplace. The firm's products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.
Contact
IPO
Employees
Officers
The intrinsic value of one NVCN stock under the Base Case scenario is 7.37 CAD.
Compared to the current market price of 40.15 CAD, Neovasc Inc is Overvalued by 82%.